Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2018—EliTechGroup Biomedical Systems released its FDA-cleared Macroduct Advanced Sweat Collection System for use in the diagnosis of cystic fibrosis. The system includes a touchscreen user interface with step-by-step graphical instructions that help standardize pilocarpine iontophoresis and sweat collection.
October 2018—PerkinElmer announced that its Euroimmun ANCA IFA and Europlus Granulocyte Mosaic assays for use with its EuroPattern microscope have received 510(k) clearance from the FDA. The Euroimmun IFA Granulocyte assays are designed as indirect immunofluorescence tests for the qualitative or semiquantitative determination of antineutrophil cytoplasmic antibodies of immunoglobulin class IgG in human serum.
October 2018—The Food and Drug Administration approved moxetumomab pasudotox-tdfk (Lumoxity, AstraZeneca), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
October 2018—Vidan Diagnostics announced the availability of its glucose test for the Lucidplus β-Ketone plus Glucose Monitoring System.
October 2018—BacterioScan received FDA 510(k) clearance for its 216Dx Urinary Tract Infection detection system for the detection of bacterial UTIs. The system uses an advanced laser sensor to rapidly detect infections, reducing lab turnaround time to three hours.
October 2018—Beckman Coulter launched its DURA Innovations Cost Benefit Calculator Tool, which allows flow cytometry customers to analyze areas of waste in the laboratory. The Cost Benefit Calculator helps the laboratory achieve greater efficiencies by identifying at least eight significant sources of waste.
October 2018—Flagship Biosciences announced that its MuscleMap algorithm that supports therapeutic development for Duchenne muscular dystrophy has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory Medicine.
October 2018—LGC Maine Standards announced the release of its Validate hsTnT kit for Roche Cobas. The kit, in a human serum matrix, is a linearity and calibration verification product that targets Roche’s Troponin T Gen 5 Stat (TnTG5) assay range.
October 2018—MDxHealth announced that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases. The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen.
October 2018—Qiagen announced a collaboration with SRL, a large clinical testing laboratory company in Japan, to prepare for introducing new companion diagnostics simultaneously with new drug approvals. The nonexclusive master collaboration agreement for clinical laboratory research services will enable rapid implementation by SRL of Qiagen’s companion diagnostic workflows upon approval of the drugs and tests by Japan’s Pharmaceuticals and Medical Devices Agency.
